{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461095969
| ImageFile = etalocib structure.png
| ImageSize = 300px
| IUPACName = 2-(3-{3-[(5-ethyl-4'-fluoro-2-hydroxybiphenyl-4-yl)oxy]propoxy}-2-propylphenoxy)benzoic acid
| OtherNames = LY293111<br/>VML 295
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 2948
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = THY6RIW44R
| InChI = 1/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
| InChIKey = YFIZRWPXUYFCSN-UHFFFAOYAU
| InChI1 = 1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
| InChIKey1 = YFIZRWPXUYFCSN-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 161172-51-6
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 329123
| PubChem = 177941
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 154905
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04074
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YFIZRWPXUYFCSN-UHFFFAOYSA-N
| SMILES = Fc1ccc(cc1)c4c(O)cc(OCCCOc3cccc(Oc2ccccc2C(=O)O)c3CCC)c(c4)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
 }}
|Section2={{Chembox Properties
| C=33 | H=33 | F=1 | O=6
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = 
 }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
 }}
}}

'''Etalocib''' is a drug candidate that was under development for the treatment of various types of cancer.<ref>{{Cite journal | pmid = 24346102| year = 2014| author1 = Jänne| first1 = P. A.| title = Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer| journal = Journal of Thoracic Oncology| volume = 9| issue = 1| pages = 126-31| last2 = Paz-Ares| first2 = L| last3 = Oh| first3 = Y| last4 = Eschbach| first4 = C| last5 = Hirsh| first5 = V| last6 = Enas| first6 = N| last7 = Brail| first7 = L| last8 = von Pawel| first8 = J| doi = 10.1097/JTO.0000000000000037}}</ref> It acts as a [[leukotriene B4 receptor]] [[Leukotriene antagonist|antagonist]] and a [[PPARγ agonist]].<ref>{{Cite journal | pmid = 19190780| year = 2008| author1 = Adrian| first1 = T. E.| title = The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer| journal = PPAR Research| volume = 2008| pages = 827096| last2 = Hennig| first2 = R| last3 = Friess| first3 = H| last4 = Ding| first4 = X| doi = 10.1155/2008/827096| pmc = 2631651}}</ref>

Clinical trials were conducted measuring efficacy for treatment of [[non-small cell lung cancer]] and [[pancreatic cancer]] and the inflammatory conditions [[asthma]], [[psoriasis]], and [[ulcerative colitis]], but were suspended due to lack of efficacy.<ref>{{cite web|title=Etalocib|url=http://adisinsight.springer.com/drugs/800003262|website=Adisinsight|accessdate=31 January 2017}}</ref>

==References==
{{Reflist}}


{{Asthma and copd rx}}
{{Leukotriene signaling modulators}}
{{PPAR modulators}}

[[Category:Leukotriene antagonists]]
[[Category:Salicylic acids]]
[[Category:Phenol ethers]]
[[Category:Fluoroarenes]]
[[Category:Abandoned drugs]]
[[Category:Biphenyls]]


{{antineoplastic-drug-stub}}